Literature DB >> 4028034

Phase II trial of gallium nitrate in patients with advanced malignant melanoma.

E S Casper, G F Stanton, P P Sordillo, R Parente, R A Michaelson, V Vinceguerra.   

Abstract

A phase II trial of gallium nitrate (250-300 mg/m2/day for 7 consecutive days) was conducted in patients with metastatic melanoma. Therapy was well-tolerated, but only one of 31 evaluable patients experienced a partial regression. Further evaluation of gallium nitrate at this dose and schedule is not warranted in patients with malignant melanoma.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4028034

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  6 in total

Review 1.  Complexes of metals other than platinum as antitumour agents.

Authors:  P Köpf-Maier
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

2.  The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines.

Authors:  Seied Mojtaba Valiahdi; Petra Heffeter; Michael A Jakupec; Rodrig Marculescu; Walter Berger; Klemens Rappersberger; Bernhard K Keppler
Journal:  Melanoma Res       Date:  2009-10       Impact factor: 3.599

3.  Phase II evaluation of gallium nitrate by continuous infusion in breast cancer.

Authors:  K Jabboury; D Frye; F A Holmes; G Fraschini; G Hortobagyi
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

Review 4.  Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

Authors:  Mukundan Baskar Mannargudi; Subrata Deb
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-17       Impact factor: 4.322

5.  Gallium ions promote osteoinduction of human and mouse osteoblasts via the TRPM7/Akt signaling pathway.

Authors:  Mingyang Yu; Yunguang Wang; Yao Zhang; Daping Cui; Guishan Gu; Dewei Zhao
Journal:  Mol Med Rep       Date:  2020-07-16       Impact factor: 2.952

6.  Gallium citrate, a new sensitizer of cells to hyperthermia.

Authors:  K Shinohara; N Kawakami; M Kugotani; H Nakano
Journal:  Jpn J Cancer Res       Date:  1988-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.